RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced that it has priced its underwritten public offering ..read more

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced its first quarter 2024 results and provided a business update ..read more

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its first quarter 2024 operating and financial results and reviewed recent business highlights ..read more

Launched in 2021, the public-private consortium on Wednesday updated ASGCT attendees on its efforts to bring adeno-associated virus gene therapies to more rare disease patients ..read more

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival for the treatment of patients with newly diagnosed, high-risk endometrial cancer after surgery with curative intent ..read more

Stevanato Group S.p.A., a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced its financial results for the first quarter of 2024 ..read more

Sonoma Pharmaceuticals, Inc. today announced the launch of its MicrocynAH animal health care products in the Menards chain of home improvement stores in the United States ..read more

Tri-Tech Forensics, Inc., a leading provider of tactical emergency medical solutions and human identification kits, is pleased to announce the acquisition of SAM® Medical, a globally renowned provider of innovative medical devices and trauma care solutions including tourniquets, hemostatics, splints, pelvic binders, and intraosseous access systems ..read more

Takeda announced financial results for fiscal year 2023, delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant loss-of-exclusivity impact ..read more

KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures and an exclusive license of KT430 to Astellas Pharmaceuticals for the treatment of X-linked myotubular myopathy ..read more